PROSPECTUS
701,664 Shares
of
Merge Technologies Incorporated
Common Stock
($0.01 par value)
This Prospectus relates to the public offering of up to 701,664 shares
of the Common Stock, par value $0.01 per share (hereinafter, the "Shares"), of
Merge Technologies Incorporated, a Wisconsin corporation doing business as
Merge eFilm (hereinafter, "we," "us" or "our"), all of which Shares may be sold
from time to time by the Selling Shareholders (described herein) or their
assignees and transferees.
In July 2003, we sold 701,664 Shares to the Selling Shareholders in an
offering exempt from the registration provisions of the Securities Act of
1933, as amended ("Securities Act"), as a non-public offering. We are obliged
to register such Shares on behalf of these persons.
The Shares trade on the Nasdaq National Market under the symbol
"MRGE." On October 13, 2003 the last reported bid price was $18.95 for the
Shares.
The Selling Shareholders (as hereinafter described) and certain
persons who purchase the Shares from the Selling Shareholders may be deemed
"Underwriters," as that term is defined in the Securities Act, as amended. The
Shares may be offered by the Selling Shareholders in one or more transactions
on the Nasdaq National Market, or in negotiated transactions or a combination
of such methods of sale, at market prices prevailing at the time of sale, at
prices related to such prevailing market prices or at negotiated prices. The
Shares may be sold by the Selling Shareholders either (i) to a broker or dealer
as principal for resale by such broker or dealer for its account pursuant to
this Prospectus (e.g., in transactions with a "market maker"), or (ii) in
brokerage transactions, including transactions in which the broker solicits
purchasers.
We will pay substantially all other expenses of this offering
(including the expense of preparing and duplicating this Prospectus and the
Registration Statement of which it is a part).
These are speculative securities. You should purchase these securities
only if you can afford a complete loss of your investment.
SEE "RISK FACTORS" ON PAGE 2 FOR INFORMATION THAT SHOULD BE CONSIDERED BY
PROSPECTIVE INVESTORS
____________________________
THIS PROSPECTUS HAS NOT BEEN REVIEWED BY THE ATTORNEY GENERAL PRIOR TO
ITS ISSUANCE AND USE. THE ATTORNEY GENERAL OF THE STATE OF NEW YORK HAS NOT
PASSED ON OR ENDORSED THE MERITS OF THIS OFFERING. ANY REPRESENTATION TO THE
CONTRARY IS UNLAWFUL. THIS PROSPECTUS DOES NOT CONTAIN AN UNTRUE STATEMENT OF
A MATERIAL FACT OR OMIT TO STATE A MATERIAL FACT NECESSARY TO MAKE THE
STATEMENTS MADE, IN LIGHT OF THE CIRCUMSTANCES UNDER WHICH THEY ARE MADE, NOT
MISLEADING. IT CONTAINS A FAIR SUMMARY OF THE MATERIAL TERMS OF DOCUMENTS
PURPORTED TO BE SUMMARIZED HEREIN.
THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE
SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION NOR HAS
THE SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION
PASSED UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO
THE CONTRARY IS A CRIMINAL OFFENSE.
The date of this Prospectus is October 14, 2003
DOCUMENTS INCORPORATED BY REFERENCE
-------------------------------------
We are incorporating in this Prospectus by reference the following
documents which we filed with the United States Securities and Exchange
Commission (hereinafter referred to as the "Commission"):
1. Our Annual Report on Form 10-KSB, as amended, for fiscal year
ended December 31, 2002.
2. Our Proxy Statement dated April 14, 2003, for our 2003 Annual
Meeting of Shareholders filed with the Commission on April 14,
2003.
3. Our Quarterly Reports on Form 10-Q, for the quarters ended
March 31, 2003 and June 30, 2003.
4. Our Current Reports on Form 8-K filed on March 6, 2003, March
11, 2003 (amending the Form 8-K for the event dated June 28,
2002), April 22, 2003, April 30, 2003, July 10, 2003, July 29,
2003, as amended on September 30, 2003, and July 30, 2003.
5. Our Form 8-A dated January 9, 1998.
6. All documents which we file subsequently to the foregoing
pursuant to Sections 13(a), 13(c), 14 and 15(d) of the
Securities Exchange Act of 1934, as amended (the "Exchange
Act"), prior to the filing of a post-effective amendment which
indicates that all securities registered have been sold or
which deregisters all securities then remaining unsold, shall
be deemed to be incorporated by reference into this
Registration Statement and to be a part hereof from the date of
filing of such documents.
Any statements contained in a document incorporated or deemed to be
incorporated by reference herein shall be deemed to be modified or superseded
for purposes of this Prospectus to the extent that a statement contained herein
or in any subsequently filed document which is also deemed to be incorporated
by reference herein modifies or supersedes such statements. Any such statement
so modified or superseded shall not be deemed, except as so modified or
superseded, to constitute part of this Prospectus.
THIS PROSPECTUS INCORPORATES DOCUMENTS BY REFERENCE WHICH ARE NOT
PRESENTED HEREIN OR DELIVERED HEREWITH. THESE DOCUMENTS (OTHER THAN EXHIBITS
THERETO) ARE AVAILABLE WITHOUT CHARGE, UPON WRITTEN OR ORAL REQUEST BY ANY
PERSON TO WHOM THIS PROSPECTUS HAS BEEN DELIVERED, FROM US. REQUESTS TO
OBTAIN SUCH DOCUMENTS SHOULD BE DIRECTED TO US AT 1126 SOUTH 70TH STREET,
MILWAUKEE, WISCONSIN 53214-3151 (TELEPHONE (414) 977-4000).
Some of the statements included in this Prospectus may be considered
to be "forward looking statements" since such statements relate to matters
which have not yet occurred. For example, phrases such as "we anticipate,"
"believe" or "expect" indicate that it is possible that the event anticipated,
believed or expected may not occur. Should such event not occur, then the
result which we expected also may not occur or may occur in a different manner,
which may be more or less favorable to us. We do not undertake any obligation
to publicly release the result of any revisions to these forward looking
statements that may be made to reflect any future events or circumstances.
Readers should carefully review the items included under the subsection
Risk Factors, as they relate to forward looking statements, as actual results
could differ materially from those projected in the forward looking statement.
SUMMARY
-----------
Purpose of the Offering. Certain of our shareholders are offering up
to 701,664 of our Shares through this Prospectus. We will not receive any of
the proceeds of the sale of any Shares sold by the Selling Shareholders.
Our Business. We are in the business of integrating radiology images
and information into healthcare enterprise networks. Our products fall into
three distinct categories: connectivity solutions; radiology workflow software
applications; and professional services. Our products and services enhance the
quality of healthcare provided to patients because they improve radiology
workflow efficiencies, reduce healthcare operating costs and improve clinical
decision making processes. We deliver this tangible value to facilities of all
sizes, but we specifically target small to medium size healthcare facilities,
multi-hospital groups, clinics and diagnostic imaging centers by working with
our customers to offer unique, phased, cost effective solutions to solve their
image and information management and radiology workflow needs. We believe that
we have been a key contributor to the development of the industry's standard
network communications protocol known as Digital Imaging Communications in
Medicine ("DICOM"), open medical standards like HL-7 and the Integrated
Healthcare Enterprise ("IHE").
Acquisition of Aurora Technology, Inc.
---------------------------------------
Through one of our wholly owned subsidiaries, Signal Stream, Inc., a
Wisconsin corporation now known as Merge Aurora Solutions Inc. ("Signal
Stream"), we acquired the assets of Aurora Technology Inc., a private Minnesota
corporation ("Aurora"). Aurora was in the business of design, production and
sale of diagnostic radiology products and software that facilitate the viewing,
distribution and storage of digital images. We are utilizing Aurora's assets
in a similar manner as Aurora.
Acquisition of eFilm Medical Inc.
----------------------------------
We also recently purchased 100% of the issued and outstanding shares
of common stock of eFilm Medical, Inc., a Nova Scotia, Canada, company
("eFilm"). eFilm has been in the business of development of medical imaging
workflow product and services and developing innovative medical image viewing
and related solutions within a clinical environment. We are utilizing eFilm's
assets in a similar manner as eFilm.
Recent Acquisition of RIS Logic, Incorporated
----------------------------------------------
On July 17, 2003, we acquired 100% of the outstanding shares of RIS
Logic, Incorporated, an Ohio corporation now known as RIS Logic, Inc. ("RIS
Logic"). RIS Logic provides comprehensive Radiology Information System ("RIS")
software and professional services for imaging centers and hospital radiology
departments to streamline operations and accelerate productivity. These
software solutions combined with professional services and training automate
the entire radiology practice workflow to decrease report turnaround time,
improve cash flow, enhance patient care and improve the operational efficiency
of imaging services.
RIS Logic provides efficient management of single or multi-site imaging
service operations, from scheduling and exam tracking to clinical information
archival, integrated billing, automated dictation/transcription, mammography
tracking and reporting, and radiologist reporting and distribution. This is
accomplished using industry-standard protocols that provide for connectivity,
integration and communication of patient data throughout the single or
multi-site imaging service operation.
RISK FACTORS
--------------
This offering involves a high degree of risk. Prospective investors
should consider carefully, among other things, the following risk factors with
respect to us and this offering.
WE HAVE NOT BEEN CONSISTENTLY PROFITABLE AND THROUGH 2000 INCURRED OPERATING
LOSSES
We incurred net losses of $1,919,970 in fiscal 1998, $2,898,821 in
fiscal 1999 and $5,707,394 in fiscal 2000, respectively. We earned net income
of $1,270,758 and $3,628,895 for the years ended December 31, 2001 and 2002,
respectively. There can be no assurance that we will continue to be profitable
in the future.
OUR OPERATING RESULTS MAY FLUCTUATE BECAUSE OF A VARIETY OF FACTORS
Our operating results are subject to quarterly and other fluctuations
due to a variety of factors. A significant portion of our business is derived
from orders placed by original equipment manufacturers ("OEMs") and direct
sales to healthcare customers. The timing of such orders could cause material
fluctuations in our business and operating results. Additionally, healthcare
capital spending and budgetary cycles could cause material fluctuations in our
direct sales from quarter to quarter. Other factors that may cause our
operating results to fluctuate include changes in sales volumes through our
distribution channels, changes in the mix of products sold, the timing of new
product announcements and introductions by us and our competitors, market
acceptance of new or enhanced versions of our products, availability and cost
of products from our suppliers, competitive pricing pressures, the gain or loss
of significant customers, increased research and development expense associated
with new product introductions and economic conditions generally or in various
geographic areas. All of the above factors are difficult for us to forecast,
and these or other factors can materially affect our operating results for one
quarter or series of quarters. In addition, our gross margins may decrease in
the future as a result of increasing sales of lower margin products or services
and volume discounts. We expect to continue to increase our operating expenses
for personnel, marketing and new product development. If we do not achieve
increased levels of sales commensurate with these increased levels of operating
expenses, our business and operating results will be materially adversely
affected. There can be no assurance that we will be profitable on a quarterly
or annual basis. Fluctuations in operating results may also result in
fluctuations in the price of our Shares.
WE MAY EXPERIENCE INCREASED CREDIT AND PAYMENT RISKS IF WE INCREASE DIRECT
SALES TO END USERS AND DECREASE SALES THROUGH VALUE ADDED RESELLERS
We currently market and sell a significant portion of our products to
OEMs and value added resellers ("VARs"). We have not, in the past, experienced
significant nonpayment or delays in payment on receivables from these
customers. Increased direct sales to end-users, such as hospitals and imaging
centers, may create delays in payment of receivables to us and may also
increase the risk of nonpayment of receivables. We may bear increased interest
expense if we experience delays in receipt of payment on receivables as a
result of increased sales directly to end-users as a percentage of total sales.
WE MAY NOT BE ABLE TO RESPOND TO TECHNOLOGICAL CHANGE
The markets for our products are characterized by rapid technological
advances and changes in customer requirements and evolving regulatory
requirements and industry standards. Our future prospects will depend, in
part, on our ability to enhance our medical image networking and information
management products in a timely manner and to identify, develop and achieve
market acceptance of new products that address new technologies and standards
and meet customer needs in the medical imaging network and information
management markets. There can be no assurance that we will be able to respond
to technological advances, changes in customer requirements or changes in
regulatory requirements or industry standards or that we will be able to
develop and market new products successfully. We are subject to risks from a
number of sources that could materially affect our ability to respond to
technological change.
WE MAY NOT BE ABLE TO RESPOND TO CHANGES IN OUR INDUSTRY OR TO THE REQUIREMENTS
OF OUR CUSTOMERS
Because the industry in which we operate is subject to rapid
technological change, we must constantly monitor industry conditions, customer
preferences and other matters. Any failure by us to anticipate or to respond
adequately to technological developments in our industry, changes in customer
requirements, changes in regulatory requirements or industry standards, or any
significant delays in the development, introduction or shipment of products,
could have a material adverse effect on our business and operating results.
In anticipation of new product introductions by us or our competitors,
customers could refrain from purchasing our existing products. New products
could render certain of our existing products obsolete. Any of these events
could materially adversely affect our business and operating results. In
addition, third-party payers, such as governmental programs and private
insurance plans, can indirectly affect the pricing or relative attractiveness
of our products by regulating the maximum amount of reimbursement that they
will provide for taking, storing and interpreting medical images. A decrease
in the reimbursement amounts for radiological procedures may decrease the
amount which physicians, clinics and hospitals are able to charge patients
for such services. As a result, adoption of new technologies may slow as
capital investment budgets are reduced, thereby significantly reducing the
demand for our products.
WE SELL OUR PRODUCTS TO A RELATIVELY LIMITED NUMBER OF CUSTOMERS, THE LOSS OF
ONE OR MORE OF WHICH COULD MATERIALLY AND ADVERSELY AFFECT US
We currently sell a material portion of our products to a relatively
limited number of OEMs, VARs and dealers. Aggregate sales to our ten largest
customers represented approximately 70%, 71%, 65%, 60%, 52% and 55% of our net
sales in 1998, 1999, 2000, 2001, 2002 and six months ended June 30, 2003,
respectively. During 1998, Marconi and Konica accounted for approximately 18%
each of our net sales. During 1999, Marconi accounted for 17% of our net sales
and Konica, Philips and Fuji accounted for approximately 11% each of our net
sales. During 2000, Fuji accounted for 14% of our net sales and Philips and
Marconi each accounted for approximately 12% of our net sales. During 2001,
Philips accounted for 16%, GE accounted for 13%, and Fuji accounted for 10% of
our net sales. During 2002, Philips accounted for 18% of our net sales. For
the six months ended June 30, 2003, Philips accounted for 17% of our net sales.
There can be no assurance that our current customers will continue to place
orders with us or that we will be able to obtain orders from new customers.
The loss of any one or more of our major customers could materially adversely
affect our business and operating results. None of our customers are subject
to any minimum purchase requirements, and many of our VAR and OEM customers
offer competitive systems manufactured by third parties. Each of our VAR and
OEM customers and dealers can cease marketing products at their respective
option, and the loss of one or more significant customers could materially
adversely affect our business and operating results.
WE MAY NOT BE ABLE TO EXPAND SUFFICIENTLY OUR SALES FORCE IN ORDER TO INCREASE
OUR SALES TO CUSTOMERS OUTSIDE OF THE UNITED STATES OF AMERICA
An important component of our business plan includes increasing our
sales to customers outside the United States of America, which represented 38%
of our net sales in fiscal 2002 and 41% of our net sales the six months ended
June 30, 2003. In order to increase overseas sales, it may be necessary or
desirable for us to expand our sales force or establish additional offices
outside of the United States of America. The increased costs of hiring new
personnel or establishing offices could have a material adverse effect on our
results of operations and financial condition.
IF WE ARE UNABLE TO RETAIN OUR KEY PERSONNEL, OUR BUSINESS MAY BE HARMED
Our continued success will depend to a significant degree upon the
efforts and abilities of our senior management, in particular, Richard A.
Linden, our President and Chief Executive Officer, William C. Mortimore, our
founder and Chief Strategist, Gregory G. Couch, Vice President and Chief
Technology Officer, Beth Frost-Johnson, Vice President, Marketing, Joseph R.
Gentile, Vice President Sales - Systems Solutions, Catherine M. McCallum, Vice
President - Healthcare Professional Services, Marketing, David M. Noshay, Vice
President, Business Development, William L. Stafford, Vice President, Sales -
OEM/VAR Solutions, Anton van Kimmenade, Vice President Service, Director
European Branch, Daniel H. Quigg, Vice President, and Scott T. Veech, Chief
Financial Officer, Secretary and Treasurer. Of these key personnel, Mr.
Linden, Mr. Mortimore, Mr. Couch, Ms. McCallum, Mr. van Kimmenade, Mr. Quigg
and Mr. Veech have employment agreements with us.
We carry key man life insurance in the amount of $2,000,000 on Richard
A. Linden and $2,000,000 on William C. Mortimore. We do not carry key man
life insurance on any other of our officers or directors. The loss of the
services of any of these persons could have a material adverse effect on us.
BECAUSE COMPETITION FOR QUALIFIED PERSONNEL IS INTENSE, WE MAY NOT BE ABLE TO
RECRUIT OR RETAIN PERSONNEL, WHICH COULD IMPACT THE DEVELOPMENT AND ACCEPTANCE
OF OUR PRODUCTS AND SERVICES
Our ability to carry out our business plan depends, in part, upon our
ability to hire and retain skilled sales and marketing professionals and
engineering specialists. Although we believe we will be able to hire
qualified personnel for such purposes, our inability to do so could materially
adversely affect our ability to market, sell and enhance our product lines.
The market for qualified experienced sales and marketing professionals and
engineering specialists has historically been, and we expect that we will
continue to be, intensely competitive. The inability to recruit and retain
qualified employees could materially adversely affect our results of
operations and financial condition.
WE HAVE BEEN ADVISED THAT A THIRD PARTY HAS THREATENED TO MAKE A CLAIM ON
CERTAIN OF OUR INTELLECTUAL PROPERTY
With the recently consummated acquisition of RIS Logic by merger into
a wholly owned subsidiary of ours, RIS Logic and three of its principal
shareholders have made detailed representations and warranties in the merger
agreement (the "Merger Agreement"), including, but not limited to, the warranty
that none of RIS Logic's intellectual property infringes upon the intellectual
property rights of others. A copy of the Merger Agreement has previously been
filed by us.
An escrow of 173,093 shares of our Common Stock was established at
closing to be the sole source of payment of indemnification claims, other than
with respect to breaches of representations and warranties associated with tax
claims, and the right to use all necessary intellectual property (whether
pursuant to ownership, license, sublicense, contract or permission), in which
event the escrowed shares would be applied as the first source of payment with
respect to such breaches.
RIS Logic has received a demand letter from counsel for Schedule Quest,
Inc. ("Schedule Quest"), alleging that RIS Logic has infringed on
Schedule Quest's Patent No. 6389454 titled "Multi-Family Scheduling System,"
which is a patent addressing computerized handling of patient scheduling. We
have retained patent counsel to address this issue. A preliminary review of
this patent suggests that the RIS Logic patent does not infringe the Schedule
Quest patent, although we cannot provide any assurances in this regard, given
the short time period since our receipt of this notice. Counsel for Schedule
Quest had previously proposed to RIS Logic's counsel that a possible business
arrangement may be achieved. We will analyze our options as to whether we will
choose to contest the patent or seek a license or other accommodation. We
believe that, in all events, that the Merger Agreement holdback is adequate
to cover any potential exposure related to such patent; however, we are
unable to guarantee that this will be the case.
IF THE PROTECTION OF OUR INTELLECTUAL PROPERTY IS INADEQUATE, OUR COMPETITORS
MAY GAIN ACCESS TO OUR TECHNOLOGY AND WE COULD LOSE CUSTOMERS.
We have received U. S. Patent No. 5,740,428 dated April 14, 1998, U. S.
Patent No. 5,950,207 dated September 7, 1999, New Zealand Patent No. 306009
dated February 7, 1996, and Australia Patent No. 704804 dated August 12, 1999,
for one aspect of our Workflow technology. A United States of America patent
has been applied for Distributed Architecture for Health Care Environment,
Patent Application No. 09/151902 underlying our MergeWeb Workflow technology.
We have also applied for additional foreign patents; however, we generally do
not rely solely on patent protection with respect to our products. Instead,
we rely on a combination of copyright and trade secret laws, employee and
third party confidentiality agreements and other measures to protect
intellectual property rights pertaining to our systems and technology. There
can be no assurance, however, that applicable copyright or trade secret laws
or these agreements will provide meaningful protection of our copyrights, trade
secrets, know-how or other proprietary information in the event of any
unauthorized use, misappropriation or disclosure of such copyrights, trade
secrets, know-how or other proprietary information. In addition, the laws of
certain foreign countries do not protect our intellectual property rights to
the same extent as do the laws of the United States of America. There can be
no assurance that third parties will not assert patent, copyright or other
intellectual property infringement claims against us with respect to our
products or technology or other matters. Any such claims against us, with or
without merit, as well as claims initiated by us against third parties, can be
time-consuming and expensive to defend or prosecute and resolve. To date, we
have not initiated any intellectual property infringement claims and no such
claims have been asserted against us.
IF WE FAIL TO COMPLY WITH UNITED STATES OF AMERICA AND FOREIGN REGULATORY
REQUIREMENTS RELATING TO OUR PRODUCTS, WE COULD BE MATERIALLY AND ADVERSELY
AFFECTED
The manufacturing and marketing of our products are subject to
government regulation as medical devices in the United States of America by the
United States Food and Drug Administration (the "FDA") and in other countries
by corresponding foreign regulatory authorities. The process of obtaining and
maintaining required regulatory clearances and approvals is lengthy, expensive
and uncertain. We believe that our success depends upon commercial sales of
improved versions of our products, certain of which cannot be marketed in the
United States of America and other regulated markets unless and until we obtain
clearance or approval from the FDA and its foreign counterparts. Failure to
comply with applicable regulatory requirements could result, among other
things, in warning letters, seizures of our products, total or partial
suspension of our production operations, refusal of the government to grant
market clearance or pre-market approval, withdrawal of approvals or criminal
prosecution.
We are also subject to other federal, state and local laws and
regulations relating to safe working conditions and manufacturing practices.
In addition, sales of our products outside the United States of America are
subject to various foreign regulatory requirements. The extent of government
regulation that might result from any future legislation or administrative
action cannot be predicted. Failure to comply with domestic regulatory
requirements or to obtain any necessary foreign certifications or regulatory
approvals, or any other failure to comply with regulatory requirements outside
the United States of America could have a material adverse effect on our
business, financial condition and results of operations.
IF WE BECOME LIABLE TO ANYONE USING ANY OF OUR PRODUCTS, WE COULD SUFFER
FINANCIALLY AND OUR REPUTATION AND CREDIBILITY IN OUR INDUSTRY COULD BE
SERIOUSLY AFFECTED
We have licensing agreements with certain of our customers which
typically contain provisions designed to limit our exposure to potential
product liability claims. However, it is possible that the limitation of
liability provisions contained in our license agreements may not be effective
under the laws of certain jurisdictions. Furthermore, although we try to
include provisions limiting our exposure to product liability in our sales
agreements, we are not always successful in doing so. Moreover, some of our
products are sold without agreements addressing product liability claims at
all. Although we have not experienced any product liability claims to date,
the sale and support of products by us may entail the risk of such claims, and
there can be no assurance that we will not be subject to such claims in the
future. Although we have procured product liability insurance, there can be no
assurance that we will continue to obtain such insurance on favorable terms or
that such insurance will be sufficient to fully protect us against a successful
product liability claim. A successful product liability claim brought against
us could have a material adverse effect on our business, results of operations,
and financial condition. Software products such as those offered by us
occasionally contain errors or failures, especially when first introduced or
when new versions are released. Although we conduct extensive product testing,
we could in the future lose or delay recognition of revenues as a result of
software errors or defects, the failure of our products to meet customer
specifications or otherwise. Although, to date, our business has not been
materially adversely affected by any such errors, defects or failure to meet
specifications, there can be no assurance that defects will not be found in
new products or releases after commencement of commercial shipments or that
such products will meet customer specifications, resulting in loss or deferral
of revenues, diversion of resources, damage to our reputation, or increased
service and warranty and other costs, any of which could have a material
adverse effect upon our business, operating results and financial condition.
WE EXPERIENCE SUBSTANTIAL COMPETITION IN OUR INDUSTRY AND OUR COMPETITORS HAVE
SOME ADVANTAGES OVER US
The markets for our products are highly competitive.
Imaging acquisition and connectivity products. We have several
competitors in the imaging acquisition and connectivity products business.
These products are sold primarily to our OEM and VAR customers who could decide
to build these capabilities internally or source these products from one of our
competitors.
* In the DICOM software development tool business, we primarily
compete directly and indirectly with a number of other
entities, including private companies like LeadTools and the
Radiological Society of North America ("RSNA"), which offers a
version of DICOM (originally developed by Mallinckrodt
Institute of Radiology) as "freeware" available to be
downloaded without charge from the Internet, but which offers
more limited features and no user support.
* We also face competition from picture archiving and
communication systems ("PACS") manufacturers that have
developed some of these tools internally and make them
available to their customers with the purchase of a complete
PACS solution.
* We face competition from two sources concerning our
connectivity products. First, as legacy x-ray devices and
specialty modalities like CTs and MRs are replaced with newer
models, the need for our connectivity products decreases
because connectivity features are built into the new
modalities. Secondly, several small specialty companies
provide similar connectivity products to the OEMs and VARs. We
anticipate competing successfully against these companies based
on our quality, feature set, and service reputation, but there
is no assurance that we will be successful in maintaining our
current run rate for this business line.
Completed PACS workflow solution sales. Our growing end-user PACS
workflow solution sales may put us more directly in competition with some of
our existing VAR customers who resell to end-users our component products as
part of their own complete PACS solution.
Many of our current and potential PACS workflow competitors have
greater resources than we have in areas including finance, research and
development, intellectual property and marketing. Many of these competitors
also have broader product lines and longer standing relationships with
customers in the medical imaging field than those we have.
We believe that our ability to compete successfully depends on a
number of factors both within and outside of our control, including:
* product innovation;
* product quality and performance;
* price;
* experienced sales, marketing and service organizations;
* rapid development of new products and features;
* continued active involvement in the development of DICOM and
other medical communication standards; and
* product and policy decisions announced by our competitors.
There can be no assurance that we will be able to compete successfully
with existing or new competitors.
WE MAY NEED ADDITIONAL CAPITAL IN THE FUTURE
We believe that existing cash, together with the availability under our
working capital line of credit and future cash flows from operations, will be
sufficient to execute our business plan during the next twelve months.
However, any projections of future cash inflows and outflows are subject to
substantial uncertainty. It may be necessary to raise additional capital to
meet long-term liquidity needs. If it is determined that additional capital is
needed, it will be raised by selling additional equity or raising debt from
third party sources. The sale of additional equity or convertible debt
securities could result in dilution to current stockholders. In addition, debt
financing, if available, could involve restrictive covenants, which could
adversely affect operations. There can be no assurance that any of these
financing alternatives, including raising additional capital, will be available
in amounts or on terms acceptable to us. If we are unable to raise any needed
additional capital, we could be required to significantly alter our operating
plan, which could have a material adverse effect on our business, financial
condition and results of operations.
IF WE ISSUE ADDITIONAL SHARES OF OUR COMMON STOCK IN CONNECTION WITH ANY FUTURE
ACQUISITIONS OF BUSINESSES, THE OWNERSHIP IN US, AND THE VALUE OF THE SHARES
OWNED BY INVESTORS COULD BE DILUTED
We may make additional acquisitions of businesses which we believe are
complementary to our business. We may make payment for such acquisitions by
issuing shares of our Common or Preferred Stock or by payment in cash. If we
choose to make payment in the form of shares of our Common or Preferred Stock,
our existing shareholders may experience a dilution in their ownership interest
in us. If we elect to make payment in the form of cash, we would have to
determine whether we will use available cash or obtain additional cash from
traditional bank financing, sources other than banks or the proceeds of the
sale of our Common or Preferred Stock. While using debt to finance
acquisitions may provide greater financial returns, it also brings with it
greater risk. Should there be a downturn in the business of the target (due
to numerous factors which could include normal downturns in the business cycle,
the departure of key employees or key accounts, inability to integrate the
target's operations into our operations, etc.), we may risk loss of our
investment. Lenders and/or equity partners also may impose restrictions upon
the manner in which we conduct our business.
WE MIGHT NOT BE ABLE TO INTEGRATE ANY BUSINESSES WHICH WE ACQUIRE WITH OUR
BUSINESSES
If we should acquire additional businesses, we face the risk that we
may not be able to integrate such acquisitions successfully with our business.
Should we be unable to integrate successfully any new business, we would be
required either to dispose of such acquisition or attempt to change the
operations of such acquisition so that it will integrate with our business.
In either event, our business operations could be materially adversely
affected.
WE WILL NOT RECEIVE ANY OF THE PROCEEDS FROM THE SALE OF SHARES BY ANY OF
THE SELLING SHAREHOLDERS IN THIS OFFERING
We will not receive any of the proceeds from sale of Shares by any of
the Selling Shareholders.
WE DO NOT HAVE ANY INTENTION TO DECLARE OR PAY ANY DIVIDENDS
We do not currently intend to declare or pay any cash dividend on our
Shares in the foreseeable future and we anticipate that earnings, if any, will
be used to finance the development and expansion of our business. Any payment
of future dividends and the amounts thereof will be dependent upon our
earnings, financial requirements and other factors deemed relevant by our
Board of Directors, including our contractual obligations.
ANY ADDITIONAL PREFERRED STOCK WHICH WE ISSUE COULD HAVE RIGHTS AND PREFERENCES
THAT COULD ADVERSELY AFFECT HOLDERS OF OUR COMMON STOCK
Our Articles of Incorporation (the "Articles") authorize the issuance
of "blank check" Preferred Stock with such designations, rights and preferences
as may be determined from time to time by the Board of Directors. Accordingly,
our Board of Directors will have the authority to issue up to 5,000,000 shares
of Preferred Stock and to determine the price, rights, preferences and
privileges of those shares without any further vote or action by the
shareholders. We issued certain shares of our Preferred Stock in connection
with our purchases of Interpra Medical Imaging Network Ltd., a corporation
incorporated under the laws of the Province of Ontario, now known as Merge
Technologies Canada Ltd. (hereinafter referred to as "Interpra"), and eFilm.
As of the date of this Prospectus, we have issued one share of Special Voting
Preferred Stock in connection with a voting trust with a financial institution
(the "Interpra Trustee") established for the benefit of holders of Interpra
Exchangeable Shares (as hereinafter defined), 22,462 of which are outstanding
as of the date of this Prospectus. We also have issued one share of Series 2
Special Voting Preferred Stock in connection with another voting trust with a
financial institution (the "eFilm Trustee") established for the benefit of
holders of eFilm Exchangeable Shares (as hereinafter defined), 336,145 of which
are outstanding as of the date of this Prospectus. There are no other shares
of Preferred Stock of any other series presently outstanding. The Special
Voting Preferred Stock and Series 2 Special Voting Preferred Stock both allow
the Interpra Trustee and the eFilm Trustee to vote at meetings of Common
Stockholders. As of the date of this Prospectus, the Interpra Trustee has
22,462 votes with regard to the Special Voting Preferred Stock and the eFilm
Trustee has 336,145 votes with regard to the Series 2 Special Voting Stock.
The rights of the holders of Shares presently may be materially adversely
affected by the rights of the holders of any additional Preferred Stock that
may be issued in the future. The issuance of Preferred Stock, while providing
desirable flexibility in connection with possible acquisitions and other
corporate purposes, could have the effect of making it more difficult for a
third party to acquire a majority of the outstanding voting stock. In
addition, if we issue more Preferred Stock with voting rights, the voting
rights of Common Stockholders would be diluted. In any event, the Common
Stockholders' percentage of equity ownership in us will be reduced if we
issue more Preferred Stock.
ANTITAKEOVER MEASURES
Our Articles and Bylaws, along with Wisconsin statutory law, contain
provisions that could discourage potential acquisition proposals and might
delay or prevent a change in control of us. Such provisions could result in
us being less attractive to a potential acquirer and could result in
shareholders receiving less for their Shares than otherwise might be available
in the event of a takeover attempt.
THE COMPANY
-------------
We are in the business of integrating radiology images and information
into healthcare enterprise networks. Our products and services enhance the
quality of healthcare provided to patients because they improve radiology
workflow efficiencies, reduce healthcare operating costs and improve clinical
decision making processes. We deliver this tangible value to facilities of
all sizes, but we specifically target small to medium size healthcare
facilities, multi-hospital groups, clinics and diagnostic imaging centers by
working with our customers to offer unique, phased, cost effective solutions
to solve their image and information management and radiology workflow needs.
We were founded in 1987 and have historically been viewed as a leading
provider of medical diagnostic imaging and information connectivity
technologies and consulting solutions for healthcare facilities worldwide.
Today, we are at the forefront of integrated radiology workflow research and
development bringing software applications to the marketplace that will enable
the seamless integration of images, information, technology and people across
the electronic healthcare enterprise. We believe that our future growth will
be driven by a continued concentration on the core aspects of our business:
targeted sales/marketing activities with broader geographic coverage; modular
product innovation; exceptional professional services; and expanding strategic
partnerships that complement our internal efforts. Our strategy is to provide
a full suite of radiology workflow solutions to our target market, which are
users of electronic image and information management systems in the healthcare
industry, including our existing domestic client base of over 400 healthcare
facilities, and to deliver functionality and value that taps into the $1.3
billion annual market.
Our products fall into three distinct categories: connectivity
solutions; radiology workflow software applications; and professional services.
Connectivity solutions continue to be one of our core competencies to maintain
our market-leading position and long-term OEM/VAR relationships. We continue
our product innovation in this area in order to provide flexible,
state-of-the-art solutions to our OEM/VAR partners who incorporate these
products directly into their new modality equipment offerings. While the
OEM/VAR relationships are central to the distribution of these products, there
is an increasing interest from healthcare organizations to purchase radiology
workflow solutions, including connectivity products, directly from us to
complete their individual image management strategies.
Through our founder and Chairman, William C. Mortimore, we believe
that we have been a key contributor to the development of the industry's
standard network communications protocol known as DICOM, open medical standards
like HL-7 and the IHE framework that has been created through an initiative
co-sponsored by the RSNA and the Healthcare Information and Management Systems
Society ("HIMSS"). The IHE initiative represents a consortium of more than
thirty companies in the Radiology and Healthcare Information Systems fields.
This set of requirements has paved the way for healthcare organizations to
begin in earnest to integrate the complex workflow systems of the radiology
department with the entire healthcare system by using equipment and software
applications that connect the various image and communication components. We
have incorporated these standards in all of our connectivity solutions and
software applications establishing the basis for seamless integration of images
and healthcare information across an organization's intranet or over the
Internet.
Radiology departments and diagnostic imaging centers and their
customers benefit from our solutions in a variety of ways including: (i)
networking of multiple image-producing and image-using devices to eliminate
duplication and reduce the need for capital equipment expenditures to build
digital image and information networks; (ii) creating permanent electronic
archives of diagnostic-quality images to enable the retrieval of these images
and reports at any time in the future; (iii) accessing our modular architecture
of products that allow radiology departments, clinics and diagnostic imaging
centers to build their electronic image and information management systems in
a phased, flexible and cost-effective way; and (iv) delivering the capability
to integrate diagnostic radiology images into the radiologist's report to make
it a permanent part of the patient's electronic medical record.
We are a Wisconsin corporation and were incorporated on November 25,
1987. Our executive offices are located at 1126 South 70th Street, Milwaukee,
Wisconsin 53214-3151. Our telephone number is (414) 977-4000, and our internet
address is www.merge-efilm.com.
Acquisition of Aurora Technology, Inc.
---------------------------------------
On May 22, 2002, we acquired, through our wholly owned subsidiary,
Signal Stream, the assets of Aurora. Aurora was in the business of design,
production and sale of diagnostic radiology products and software that
facilitate the viewing, distribution and storage of digital images. Its assets
included accounts receivable, inventory, capital equipment and intangible
assets. We are utilizing Aurora's assets in a similar manner as Aurora.
The purchase price was 93,901 non-registered Shares, plus $100,000 in
cash. Twenty percent of the Shares have been held in escrow for twelve months
to secure obligations of Aurora. We filed a registration statement with the
Commission with respect to the 93,901 Shares issued in this transaction.
The consideration was negotiated at arms-length between us and Aurora
and includes a premium over the book value of assets, based on our own
assessment of the market value of Aurora's assets and the benefits of combining
Aurora with us.
Acquisition of eFilm Medical Inc.
----------------------------------
On June 28, 2002, we, Merge Technologies Holdings Co., a Nova Scotia
unlimited liability company ("Merge Holdings"), and eFilm, pursuant to the
terms of a Reorganization Agreement, completed certain transactions wherein,
among other things, we acquired 100% of the issued and outstanding shares of
eFilm common stock. As part of the transactions contemplated under the
Reorganization Agreement, shares of common stock previously outstanding of
eFilm were converted into 1,000,000 exchangeable shares of eFilm (the "eFilm
Exchangeable Shares"). Each eFilm Exchangeable Share is exchangeable and
convertible into one Share. We filed a registration statement with the
Commission with respect to the 1,000,000 Shares made available to the
stockholders of eFilm in exchange of the eFilm Exchangeable Shares at such time
as they elect to make the exchange.
eFilm has been in the business of development of medical imaging
workflow products and services, and developing innovative medical image viewing
and related solutions within a clinical environment. Its assets included
accounts receivable, inventory, capital equipment and intangible assets. We
are utilizing the eFilm assets in a similar manner as eFilm. Prior to this
transaction with eFilm, we entered into a joint development and technology
sharing agreement with eFilm wherein we agreed to cross license certain
technologies and jointly develop image distribution technologies under the
ImageChannelTM label.
The consideration was negotiated at arms-length between us and eFilm
and includes a premium over the book value of assets, based on our own
assessment of the market value of eFilm's assets and the benefits of
combining eFilm with us.
Recent Acquisition of RIS Logic, Incorporated
----------------------------------------------
On July 17, 2003, we acquired 100% of the outstanding shares of RIS
Logic in exchange for 772,000 shares of our common stock, cash of $2,724,000,
the payment of $1,700,000 of liabilities as a closing condition of the sale and
the issuance of 128,000 options to replace existing fully vested options
previously issued to RIS Logic employees from the Merge Technologies
Incorporated 2003 Stock Option Plan. We have filed a registration statement to
register shares issued from said Plan.
RIS Logic has been in the business of the development and sales of RIS
to end user imaging centers. Its assets included accounts receivable, capital
equipment and intangible assets. We intend to utilize the RIS Logic assets in
a similar manner as RIS Logic.
The consideration was negotiated at arms-length between us and RIS
Logic and includes a premium over the book value of assets, based on our own
assessment of the market value of RIS Logic's assets and the benefits of
combining RIS Logic with us.
USE OF PROCEEDS
-----------------
We will not receive any cash proceeds from the sale of any of the
Shares by the Selling Shareholders.
SELLING SHAREHOLDERS
----------------------
The Selling Shareholders or their assignees and transferees may offer
up to 701,664 Shares pursuant to this Prospectus. We will not receive any of
the proceeds from the sale of the Shares by the Selling Shareholders.
The following table sets forth certain information with respect to the Selling
Shareholders and the Shares which they presently own.
Shares to be
Shares Beneficially Shares Beneficially
Owned Prior to Being Owned After
Selling Shareholders Offering Offered Offering (1)
-------------------------------------- -------------------- --------- -------------------------
Number Percent Number Percent
------- ---------- --------- ---------
BayStar Capital II, L.P. (2).......... 100,000 * 100,000 ---- 0
CD Investment Partners, Ltd. (3)...... 25,000 * 25,000 ---- 0
Crestview Capital Fund II, LP (4)..... 83,333 * 83,333 ---- 0
North Sound Legacy International
Ltd. (5)............................ 83,333 * 83,333 ---- 0
North Sound Legacy Institutional Fund
LLC (5)............................. 75,833 * 75,833 ---- 0
North Sound Legacy Fund LLC (5)....... 7,500 * 7500 ---- 0
Pequot Navigator Onshore Fund,
L.P. (6)............................ 45,908 * 45,908 ---- 0
Pequot Scout Fund, L. P. (6).......... 83,832 * 83,832 ---- 0
Pequot Navigator Offshore Fund,
Inc. (6)............................ 36,926 * 36,926 ---- 0
Royal Bank of Canada (7).............. 83,333 * 83,333 ---- 0
Richard P. Kiphart.................... 41,666 * 41,666 ---- 0
Belle Haven Investments, L.P. (8)..... 17,500 * 17,500 ---- 0
Gary M. Glaser........................ 17,500 * 17,500 ---- 0
------- -------
701,664 701,664
*Less than one percent
(1) Assumes the sale of all Shares offered by this Prospectus.
(2) Steve Derby, Steven M. Lamar and Lawrence Goldfarb, the Managing Members,
exercise voting and investment powers over these Shares on behalf of this
Selling Shareholder.
(3) John D. Ziegelman, Director, exercises voting and investment powers over
these Shares on behalf of this Selling Shareholder.
(4) Richard Levy, Managing Member, exercises voting and investment powers
over these Shares on behalf of this Selling Shareholder.
(5) Thomas McAuley, Chief Investment Officer, exercises voting and
investment powers over these Shares on behalf of this Selling Shareholder.
(6) Arthur Sandberg, a prinicpal of Pequot Capital Management Inc., which is
the investment manager for this Selling Shareholder, exercises voting and
investment powers over these Shares on behalf of this Selling Shareholder.
(7) Johan Wahlstedt, Managing Director, exercises voting and investment
powers over these Shares on behalf of this Selling Shareholder.
(8) Gary M. Glaser, General Partner, exercises voting and investment powers
over these Shares on behalf of this Selling Shareholder.
Under the Exchange Act, and the regulations thereunder, any person
engaged in a distribution of the Shares offered by this Prospectus may not
simultaneously engage in market-making activities with respect to the Shares
during the applicable "cooling off" period prior to the commencement of such
distribution. In addition, and without limiting the foregoing, the Selling
Shareholders will be subject to applicable provisions of the Securities Act
and the Exchange Act and the rules and regulations thereunder, including,
without limitation, Regulation M under the Securities Act, in connection with
transactions in the Shares, which provisions may limit the timing of purchases
and sales of Shares.
PLAN OF DISTRIBUTION
----------------------
This Prospectus, as appropriately amended or supplemented, may be used
from time to time by the Selling Shareholders, or their transferees, to offer
and sell the Shares in transactions in which the Selling Shareholders and any
broker-dealer through whom any of the Shares are sold may be deemed to be
Underwriters within the meaning of the Securities Act. We will not receive any
of the proceeds from any such sales. There presently are no arrangements or
understandings, formal or informal, pertaining to the distribution of the
Shares.
We anticipate that resales of the Shares by the Selling Shareholder
will be effected from time to time on the open market in ordinary brokerage
transactions in the Nasdaq National Market, on which the Shares are included
for quotation, in the over-the-counter market, or in private transactions. The
Shares will be offered for sale at market prices prevailing at the time of sale
or at negotiated prices and on terms to be determined when the agreement to
sell is made or at the time of sale, as the case may be. The Shares may be
offered directly by the Selling Shareholders or through brokers or dealers. A
member firm of the National Association of Securities Dealers, Inc. ("NASD")
may be engaged to act as the Selling Shareholders' agent in the sale of the
Shares by the Selling Shareholders and/or may acquire Shares as principal.
Member firms participating in such transactions as agent may receive
commissions from the Selling Shareholders (and, if they act as agent for the
purchaser of such Shares, from such purchaser), such commissions computed, in
appropriate cases, in accordance with the applicable rates of the NASD, which
commissions may be negotiated rates where permissible. Sales of the Shares by
the member firm may be made on the Nasdaq National Market from time to time at
prices related to prices then prevailing.
Participating broker-dealers may agree with the Selling Shareholders to
sell the specified number of Shares at a stipulated price per Share and, to the
extent such broker dealer is unable to do so acting as agent for the Selling
Shareholders, to purchase as principal any unsold Shares at the price required
to fulfill the broker-dealer's commitment to the Selling Shareholders.
Broker-dealers who acquire Shares as principal may thereafter resell such
Shares from time to time in transactions on the Nasdaq National Market, in
negotiated transactions, or otherwise, at market prices prevailing at the time
of sale or at negotiated prices.
Upon the Selling Shareholders notifying us that a particular offer
to sell the Shares is made and a material arrangement has been entered into
with a broker-dealer for the sale of Shares, a supplement to this Prospectus
will be delivered together with this Prospectus and filed pursuant to Rule
424(b) under the Securities Act setting forth with respect to such offer or
trade the terms of the offer or trade, including: (i) the number of Shares
involved; (ii) the price at which the Shares were sold; (iii) any
participating brokers, dealers, agents or member firm involved; (iv) any
discounts, commissions and other items paid as compensation from, and the
resulting net proceeds to, the Selling Shareholders; and (v) other facts
material to the transaction.
Shares may be sold directly by the Selling Shareholders or through
agents designated by the Selling Shareholders from time to time. Unless
otherwise indicated in the supplement to this Prospectus, any such agent
will be acting on a best efforts basis for the period of its appointment.
The Selling Shareholders and any brokers, dealers, agents, member
firm or others that participate with the Selling Shareholders in the
distribution of the Shares may be deemed to be Underwriters within the meaning
of the Securities Act, and any commissions or fees received by such persons and
any profit on the resale of the Shares purchased by such person may be deemed
to be underwriting commissions or discounts under the Securities Act.
DESCRIPTION OF SECURITIES
---------------------------
Our authorized capital stock consists of 30,000,000 shares of Common
Stock, and 5,000,000 shares of Preferred Stock, par value $0.01 per share, of
which we have designated 1,000,000 shares as Series A Preferred Stock, one
share of Special Voting Preferred Stock and one share of Series 2 Special
Voting Preferred Stock. As of October 13, 2003, there were 12,424,614 shares
of Common Stock (inclusive of the Shares held in escrow per the RIS Logic
Merger Agreement), no shares of Series A Preferred Stock, one share of Special
Voting Preferred Stock and one share of Series 2 Special Voting Preferred Stock
outstanding.
The following description of our capital stock is a summary and is
qualified in its entirety by the provisions of our Articles and Bylaws, copies
of which are available for review upon request.
COMMON STOCK
-------------
Holders of Shares are entitled to one vote per share on each matter
submitted to a vote at a meeting of stockholders. The Shares do not have
cumulative voting rights, which means that the holders of a majority of voting
Shares voting for the election of directors can elect all of the members of the
Board of Directors. The Shares have no preemptive rights and no redemption or
conversion privileges. Subject to any preferences of any outstanding Preferred
Stock, the holders of the outstanding Shares are entitled to receive dividends
out of assets legally available at such times and in such amounts as the Board
of Directors may, from time to time, determine, and upon liquidation and
dissolution are entitled to receive all assets available for distribution to
the stockholders. A majority vote of Shares represented at a meeting at which
a quorum is present is sufficient for most actions that require the vote of
stockholders. All of the outstanding Shares are fully-paid and non-assessable.
(See "Certain Statutory and Other Provisions.")
PREFERRED STOCK
---------------
Our Board of Directors may, without further action by our stockholders,
from time to time, issue shares of Preferred Stock in series and may, at the
time of issuance, determine the rights, preferences and limitations of each
series. Any dividend preference of any Preferred Stock which may be issued
would reduce the amount of funds available for the payment of dividends on
Shares. Also, holders of Preferred Stock would normally be entitled to receive
a preference payment in the event of any liquidation, dissolution, or
winding-up of us before any payment is made to the holders of Shares. Under
certain circumstances, the issuance of such Preferred Stock may render more
difficult or tend to discourage a merger, tender offer, proxy contest, the
assumption of control by a holder of a large block of our securities or the
removal of incumbent management. Although we presently have no plans to issue
any additional shares of Preferred Stock, the Board of Directors, without
stockholder approval, may issue Preferred Stock with voting and conversion
rights which could adversely affect the holders of Shares.
Series A Preferred Stock. There presently are no shares of Series A
Preferred Stock outstanding. However, the Certificate of Designations for the
Series A Preferred Stock provides that holders of Series A Preferred Stock are
entitled to receive dividends at the rate of 8% per annum, payable in quarterly
installments in cash or in Shares, at the discretion of our Board of Directors.
If we are liquidated, holders of Series A Preferred Stock are entitled to
receive a liquidation preference in an amount equal to the stated value of the
Series A Preferred Stock less any distributions of assets and funds distributed
to holders of Series A Preferred Stock, including dividends and/or redemption
proceeds from redemptions of Series A Preferred Stock, and including all
accrued and unpaid dividends.
The Series A Preferred Stock ranks senior to the Shares and all other
Preferred Stock which is junior to the Series A Preferred Stock.
The Series A Preferred Stock is convertible, at any time and from time
to time, at the sole discretion of the holder of Series A Preferred Stock, into
Shares at the rate of one share of Series A Preferred Stock for one share of
Common Stock, subject to adjustment as set forth in our Certificate of
Designations for the Series A Preferred Stock. Upon the occurrence of both of
(i) the closing bid price of our Shares at $4.00 or more for thirty (30)
consecutive trading days on the Nasdaq National Market or any other exchange
or trading market on which our Shares are traded, and (ii) registration of the
Shares underlying the Series A Preferred Stock with the Commission, then the
Series A Preferred Stock automatically converts into Shares.
The Series A Preferred Stock will be adjusted in the event of a capital
reorganization or reclassification, consolidation, merger or other business
combination.
Each share of Series A Preferred Stock is entitled to cast a number of
votes equal to the number of Shares into which each share of Series A Preferred
Stock is convertible. Holders of Series A Preferred Stock and Common
Stockholders are entitled to vote as one class on all matters as to which
shareholders are entitled to vote, unless otherwise provided by applicable law.
Special Voting Preferred Stock. In September 1999, we, Merge Holdings,
Interpra, and the principal shareholders of Interpra, pursuant to a Purchase
Agreement (the "Interpra Agreement"), completed certain transactions wherein,
among other things, we acquired 100% of the issued and outstanding shares of
Interpra common stock. As part of the transactions contemplated under the
Interpra Agreement, shares of Interpra common stock previously outstanding
were exchanged for and converted into 420,000 exchangeable shares of Interpra
(the "Interpra Exchangeable Shares"). Each Interpra Exchangeable Share is
exchangeable and convertible into one share of Common Stock. Also in connection
with our acquisition of Interpra, we issued one share of Special Voting
Preferred Stock to the Interpra Trustee pursuant to a Trust Agreement (the
"Interpra Trust Agreement") dated September 3, 1999, to which the Interpra
Trustee, Interpra and we are parties.
The Interpra Trustee, as the holder of the Special Voting Preferred
Stock, is not entitled to receive dividends. If we are liquidated, the holder
of the Special Voting Preferred Stock is entitled to receive a liquidation
preference in an amount equal to the stated value of the Special Voting
Preferred Stock, less any distributions of assets and funds distributed to
the holder of the Special Voting Preferred Stock, including redemption
proceeds from redemptions of the Special Voting Preferred Stock.
The Special Voting Preferred Stock ranks senior to our Shares, pari
passu to the Series 2 Special Voting Preferred Stock (as hereinafter
described), and junior to any other class or series of our capital stock.
The Special Voting Preferred Stock is not subject to redemption,
except that at such time as no Interpra Exchangeable Shares (other than
Interpra Exchangeable Shares owned by us and our affiliates) are outstanding,
and no shares of stock, debt, options or other agreements which could give
rise to the issuance of any Interpra Exchangeable Shares to any person (other
than us and our affiliates) shall exist; then the Special Voting Preferred
Stock shall automatically be redeemed and canceled, for an amount equal to
$0.01 due and payable upon such redemption. Upon any such redemption or
other purchase or acquisition of the Special Voting Preferred Stock by us,
the Special Voting Preferred Stock shall be deemed retired and canceled and
may not be reissued.
The holder of record of the Special Voting Preferred Stock shall be
entitled to cast a number of votes equal to the number of Interpra Exchangeable
Shares outstanding from time to time (other than the Interpra Exchangeable
Shares held by us and our affiliates).
Pursuant to the terms of the Interpra Trust Agreement, during the
term of the Interpra Trust Agreement, we may not, without the consent of the
holders of the Interpra Exchangeable Shares, issue any additional shares of
our Special Voting Preferred Stock. The Special Voting Preferred Stock
entitles the holder of record to a number of votes at meetings of holders of
our Shares equal to the number of Interpra Exchangeable Shares outstanding
from time to time (other than the Interpra Exchangeable Shares held by us and
our affiliates). The Interpra Trustee shall vote the Special Voting Preferred
Stock in accordance with instructions which it has received from the holders
of the Interpra Exchangeable Shares. The voting rights attached to the Special
Voting Preferred Stock shall terminate pursuant to and in accordance with the
Interpra Trust Agreement.
Series 2 Special Voting Preferred Stock. In June 2002, we, Merge
Holdings, eFilm and the principal shareholders of eFilm, pursuant to a
Reorganization Agreement (the "eFilm Agreement") completed certain transactions
wherein, among other things, we acquired 100% of the issued and outstanding
shares of eFilm common stock. As part of the transactions contemplated under
the eFilm Agreement, shares of common stock of eFilm previously outstanding
were exchanged for and converted into 1,000,000 exchangeable shares of eFilm.
Each eFilm Exchangeable Share is exchangeable and convertible into one share
of Common Stock. Also in connection with our acquisition of eFilm, we issued
one share of Series 2 Special Voting Stock to the eFilm Trustee pursuant to
a Trust Agreement (the "eFilm Trust Agreement") dated June 28, 2002, to which
the eFilm Trustee, eFilm and we are a party.
The eFilm Trustee, as the holder of the Series 2 Special Voting
Preferred Stock, is not entitled to receive dividends. If we are liquidated,
the holder of the Series 2 Special Voting Preferred Stock is entitled to
receive a liquidation preference in an amount equal to the stated value of
the Series 2 Special Voting Preferred Stock less any distributions of assets
and funds distributed to the holder of the Series 2 Special Voting Preferred
Stock, including redemption proceeds from redemptions of the Series 2 Special
Voting Preferred Stock.
The Series 2 Special Voting Preferred Stock ranks senior to our
Shares, pari passu to the Special Voting Preferred Stock, and junior to any
other class or series of our capital stock.
The Series 2 Special Voting Preferred Stock shall not be subject to
redemption, except that at such time as no eFilm Exchangeable Shares (other
than eFilm Exchangeable Shares owned by us and our affiliates) shall be
outstanding, and no shares of stock, debt, options or other agreements which
could give rise to the issuance of any eFilm Exchangeable Shares to any person
(other than us and our affiliates) shall exist; then the Series 2 Special
Voting Preferred Stock shall automatically be redeemed and canceled, for an
amount equal to $0.01 due and payable upon such redemption. Upon any such
redemption or other purchase or acquisition of the Series 2 Special Voting
Preferred Stock by us, the Series 2 Special Voting Preferred Stock shall be
deemed retired and canceled and may not be reissued.
The holder of record of the Series 2 Special Voting Share shall be
entitled to cast a number of votes equal to the number of eFilm Exchangeable
Shares outstanding from time to time (other than the eFilm Exchangeable
Shares held by us and our affiliates).
Pursuant to the terms of the eFilm Trust Agreement, during the term
of the eFilm Trust Agreement, we may not, without the consent of the holders
of the eFilm Exchangeable Shares, issue any additional shares of our Series
2 Special Voting Preferred Stock. The Series 2 Special Voting Preferred Stock
entitles the holder of record to a number of votes at meetings of holders of
Shares equal to the number of eFilm Exchangeable Shares outstanding from time
to time (other than the eFilm Exchangeable Shares held by us and our
affiliates). The Trustee shall vote the Series 2 Special Voting Preferred
Stock in accordance with instructions which it has received from the holders
of the eFilm Exchangeable Shares. The voting rights attached to the Series
2 Special Voting Preferred Stock shall terminate pursuant to and in accordance
with the Trust Agreement.
EXCHANGEABLE SHARES
----------------------
Certain former stockholders of eFilm and Interpra were issued shares
exchangeable into shares of our Common Stock. As of the date of this
Prospectus, holders of eFilm Exchangeable Shares have the right to receive up
to 336,145 Shares and holders of Interpra Exchangeable Shares have the right
to receive up to 22,462 Shares.
LIMITATION OF DIRECTOR LIABILITY
---------------------------------
Section 180.0828 of the Wisconsin Business Corporation Law ("WBCL")
provides that officers and directors of domestic corporations may be personally
liable only for intentional breaches of fiduciary duties, criminal acts,
transactions from which the director derived an improper personal profit and
willful misconduct. These provisions may have the effect of reducing the
likelihood of derivative litigation against directors and may discourage or
deter shareholders or management from bringing a lawsuit against directors for
breach of their duty of care, even though such an action, if successful, might
otherwise have benefited us and our shareholders. The employment agreements of
certain directors and officers contain a provision similar to the provisions
of the WBCL.
INDEMNIFICATION
----------------
Under the WBCL, our directors and officers are entitled to mandatory
indemnification from us against certain liabilities and expenses (a) to the
extent such officers or directors are successful in the defense of a
proceeding, and (b) in proceedings in which the director or officer is not
successful in the defense thereof, unless (in the latter case only) it is
determined that the director or officer breached or failed to perform his or
her duties to us and such breach or failure constituted: (i) a willful
failure to deal fairly with us or our shareholders in connection with a matter
in which the director or officer had a material conflict of interest; (ii) a
violation of the criminal law unless the director or officer had reasonable
cause to believe his or her conduct was lawful or had no reasonable cause to
believe his or her conduct was unlawful; (iii) a transaction from which the
director or officer derived an improper personal profit; or (iv) willful
misconduct. The WBCL allows a corporation to limit its obligation to indemnify
officers and directors by providing so in its articles of incorporation. Our
Bylaws provide for indemnification of directors and officers to the fullest
extent permitted by Wisconsin law.
CERTAIN STATUTORY AND OTHER PROVISIONS
---------------------------------------
The provisions of our Bylaws and the WBCL described in this section
may delay or make more difficult acquisitions or changes of control of us not
approved by our Board of Directors. Such provisions have been implemented to
enable us, particularly (but not exclusively) in the initial years of our
existence as a publicly-traded company, to develop our business in a manner
which will foster its long-term growth without disruption caused by the threat
of a takeover not deemed by its Board of Directors to be in our best interests
and our shareholders. Such provisions could have the effect of discouraging
third parties from making proposals involving an acquisition or change of
control of us although such proposals, if made, might be considered desirable
by a majority of our shareholders. Such provisions may also have the effect of
making it more difficult for third parties to cause the replacement of our
current management without the concurrence of the Board of Directors.
Number of Directors; Removal; Vacancies. The Bylaws currently provide
that the number of Directors shall be not less than three nor greater than
eleven. The authorized number of Directors may be changed by amendment of the
Bylaws. The Bylaws also provide that our Board of Directors shall have the
exclusive right to fill vacancies on the Board of Directors, including
vacancies created by expansion of the Board or removal of a Director, and
that any Director elected to fill a vacancy shall serve until the next annual
meeting of shareholders. The Bylaws further provide that Directors may be
removed by the shareholders only by the affirmative vote of the holders of at
least a majority of the votes then entitled to be cast in an election of
Directors. This provision, in conjunction with the provisions of the Bylaws
authorizing the Board to fill vacant Directorships, could prevent shareholders
from removing incumbent Directors and filling the resulting vacancies with
their own nominees.
Amendments to the Articles of Incorporation. The WBCL provides
authority to us to amend our Articles at any time to add or change a provision
that is required or permitted to be included in the Articles or to delete a
provision that is not required to be included in the Articles. Our Board of
Directors may propose one or more amendments to our Articles for submission
to shareholders and may condition its submission of the proposed amendment on
any basis if the Board of Directors notifies each shareholder, whether or not
entitled to vote, of the shareholders' meeting at which the proposed amendment
will be voted upon.
Constituency or Stakeholder Provision. Under Section 180.0827 of the
WBCL (the "Wisconsin Stakeholder Provision"), in discharging his or her duties
to us and in determining what he or she believes to be in our best interests
of, a director or officer may, in addition to considering the effects of any
action on shareholders, consider the effects of the action on employees,
suppliers, customers, the communities in which we operate and any other factors
that the director or officer considers pertinent.
Wisconsin Antitakeover Statutes. Sections 180.1140 to 180.1144 of the
WBCL (the "Wisconsin Business Combination Statute") regulate the broad range
of "business combinations" between a "resident domestic corporation" (such as
us) and an "interested stockholder." The Wisconsin Business Combination
Statute defines a "business combination" to include a merger or share exchange,
or a sale, lease, exchange, mortgage, pledge, transfer or other disposition of
assets equal to at least 5% of the market value of the stock or assets of the
corporation or 10% of its earning power, or the issuance of stock or rights to
purchase stock with a market value equal to at least 5% of the outstanding
stock, the adoption of a plan of liquidation or dissolution and certain other
transactions involving an "interested stockholder," defined as a person who
beneficially owns 10% of the voting power of the outstanding voting stock of
the corporation or who is an affiliate or associate of the corporation and
beneficially owned 10% of the voting power of the then outstanding voting
stock within the last three years. Section 180.1141 of the Wisconsin Business
Combination Statute prohibits a corporation from engaging in a business
combination (other than a business combination of a type specifically excluded
from the coverage of the statute) with an interested stockholder for a period
of three years following the date such person becomes an interested
stockholder, unless the board of directors approved the business combination
or the acquisition of the stock that resulted in a person becoming an
interested stockholder before such acquisition. Accordingly, the Wisconsin
Business Combination Statute's prohibition on business combinations cannot be
avoided during the three year period by subsequent action of the board of
directors or shareholders. Business combinations after the three year period
following the stock acquisition date are permitted only if (i) the board of
directors approved the acquisition of the stock by the interested stockholder
prior to the acquisition date, (ii) the business combination is approved by
a majority of the outstanding voting stock not beneficially owned by the
interested stockholder, or (iii) the consideration to be received by
shareholders meets certain requirements of the statute with respect to
form and amount.
In addition, the WBCL provides in Sections 180.1130 to 180.1133 that
business combinations involving a "significant shareholder" (as defined below)
and a "resident domestic corporation" (such as us) are subject to a two-thirds
supermajority vote of shareholders (the "Wisconsin Fair Price Statute"), in
addition to any approval otherwise required. A "significant shareholder," with
respect to a resident domestic corporation, is defined as a person who
beneficially owns, directly or indirectly, 10% or more of the voting stock of
the corporation, or an affiliate of the corporation which beneficially owned,
directly or indirectly, 10% or more of the voting stock of the corporation
within the last two years. As a result of completing our initial public
offering of our Shares in 1998, we are an "issuing public corporation." Under
Section 180.1131 and Section 180.1132 of the WBCL, the business combinations
described above must be approved by 80% of the voting power of the
corporation's stock and at least two-thirds of the voting power of the
corporation's stock not beneficially held by the significant shareholder who
is party to the relevant transaction or any of its affiliates or associates,
in each case voting together as a single group, unless the following fair
price standards have been met: (i) the aggregate value of the per share
consideration is equal to the higher of (a) the highest price paid for any
Shares of the corporation by the significant shareholder in the transaction
in which it became a significant shareholder of within two years before the
date of the business combination, (b) the market value of the corporation's
shares on the date of commencement of any tender offer by the significant
shareholder, the date on which the person became a significant shareholder
or the date of the first public announcement of the proposed business
combination, whichever is highest, or (c) the highest liquidation or
dissolution distribution to which holders of the shares would be entitled;
and (ii) either cash, or the form of consideration used by the significant
shareholder to acquire the largest number of shares, is offered.
Section 180.1134 of the WBCL (the "Wisconsin Defensive Action
Restrictions") provides that, in addition to the vote otherwise required by
law or the articles of incorporation of an issuing public corporation, the
approval of the holders of a majority of the shares entitled to vote is
required before such corporation can take certain action while a takeover
offer is being made or after a takeover offer has been publicly announced and
before it is concluded. Under the Wisconsin Defensive Action Restrictions,
shareholder approval is required for the corporation to (i) acquire more than
5% of the outstanding voting shares at a price above the market price from any
individual who or organization which owns more than 3% of the outstanding
voting shares and has held such shares for less than two years, unless a
similar offer is made to acquire all voting shares, or (ii) sell or option
assets of the corporation which amount to at least 10% of the market value
of the corporation, unless the corporation has at least three independent
directors (directors who are not officers or employees) and a majority of the
independent directors vote not to have this provision apply to the corporation.
The restrictions described in clause (i) above may have the effect of deterring
a shareholder from acquiring Shares with the goal of seeking to have us
repurchase such shares at a premium over the market price.
Section 180.1150 of the WBCL provides that the voting power of shares
of public Wisconsin corporations such as us held by any person or persons
acting as a group in excess of 20% of the voting power in the election of
directors is limited to 10% of the full voting power of those shares. This
statutory voting restriction does not apply to shares acquired directly from
us or in certain specified transactions or shares for which full voting power
has been restored pursuant to a vote of shareholders.
Certain Antitakeover Effects. Certain provisions of our Articles and
Bylaws may have significant antitakeover effects, including the ability of the
remaining directors to fill vacancies, and the ability of the Board of
Directors to issue "blank check" Preferred Stock which, in turn, allows the
directors to adopt a so-called "rights plan" which would entitle shareholders
(other than a hostile bidder) to acquire our stock at a discount.
The explicit grant in the Wisconsin Stakeholder Provision of
discretion to directors to consider nonshareholder constituencies could, in
the context of an "auction" of us, have antitakeover effects in situations
where the interests of our stakeholders, including employees, suppliers,
customers and communities in which we do business, conflict with the
short-term maximization of shareholder value.
The Wisconsin Fair Price Statute may discourage any attempt by a
shareholder to squeeze out other shareholders without offering an appropriate
premium purchase price. In addition, the Wisconsin Defensive Action
Restrictions may have the effect of deterring a shareholder from acquiring
Shares with the goal of seeking to have us repurchase Shares at a premium. The
WBCL statutory provisions and our Article and Bylaw provisions referenced above
are intended to encourage persons seeking to acquire control of us to initiate
such an acquisition through arms-length negotiations with our Board of
Directors and to ensure that sufficient time for consideration of such a
proposal, and any alternatives, is available. Such measures are also designed
to discourage investors from attempting to accumulate a significant minority
position in us and then use the threat of a proxy contest as a means to
pressure us to repurchase Shares at a premium over the market value. To the
extent that such measures make it more difficult for, or discourage, a proxy
contest or the assumption of control by a holder of a substantial block of
Shares, they could increase the likelihood that incumbent Directors will retain
their positions and may also have the effect of discouraging a tender offer or
other attempt to obtain control of us, even though such attempt might be
beneficial to us and its shareholders.
TRANSFER AGENT
---------------
The transfer agent for our Shares is American Stock Transfer & Trust
Company.
LEGAL MATTERS
---------------
The validity of the issuance of the Shares offered hereby has been
passed on for us by Herrling, Clark, Hartzheim & Siddall, Ltd., as special
securities counsel to us for this offering. We are represented by Shefsky &
Froelich Ltd. for other corporate and securities law matters.
EXPERTS
----------
The consolidated financial statements of Merge Technologies
Incorporated as of December 31, 2002 and 2001, and for each of the years in the
three-year period ended December 31, 2002, have been incorporated by reference
herein and in the Registration Statement in reliance upon the report of KPMG
LLP, independent accountants, incorporated by reference herein, and upon the
authority of said firm as experts in accounting and auditing. The audit report
covering the December 31, 2002 consolidated financial statements refers to the
adoption of the provisions of Statement of Financial Accounting Standards No.
142, "Goodwill and Other Intangible Assets," on January 1, 2002.
AVAILABLE INFORMATION
We have filed with the Commission a Registration Statement (of which
this Prospectus is a part) on Form S-3 under the Securities Act with respect
to the Shares offered hereby. This Prospectus does not contain all of the
information set forth in the Registration Statement, certain parts of which are
omitted in accordance with the rules and regulations of the Commission. The
Registration Statement and any amendments thereto, including exhibits filed as
a part thereof, are available for inspection and copying as set forth below.
We are subject to the informational requirements of the Exchange Act,
and in accordance therewith, file reports, proxy statements and other
information with the Commission. These reports, proxy statements and other
information can be inspected and copied at the public reference facilities of
the Commission, Room 1024, 450 Fifth Street, N. W., Washington, D.C. 20549.
Copies of this material can be obtained from the Public Reference Section of
the Commission at 450 Fifth Street, N. W., Washington, D. C. 20549, at
prescribed rates. Our Shares are included for quotation on the Nasdaq National
Market and these reports, proxy statements and other information concerning us
may be inspected at the office of the Nasdaq Market, 1735 K Street, N. W.,
Washington, D. C. 20006.
No dealer, salesperson or other person 701,664 SHARES
has been authorized to give any
information or to make any representations
other than those contained in this Prospectus
and, if given or made, such information or
representations must not be relied upon as
having been authorized by the Company. This MERGE TECHNOLOGIES INCORPORATED
Prospectus does not constitute an offer to
sell or a solicitation of an offer to buy to
any person in any jurisdiction in which such
offer or solicitation would be unlawful or to
any person to whom it is unlawful. Neither
the delivery of this Prospectus nor any offer
or sale made hereunder shall, under any
circumstances, create any implication that COMMON STOCK
there has been no change in the affairs of ($0.01 par value)
the Company or that information contained
herein is correct as of any time subsequent
to the date hereof. PROSPECTUS
----------
TABLE OF CONTENTS
-------------------
Page
----
DOCUMENTS INCORPORATED BY REFERENCE.......... 1
SUMMARY...................................... 2
RISK FACTORS................................. 2
THE COMPANY.................................. 9
USE OF PROCEEDS.............................. 11
SELLING SHAREHOLDERS......................... 11
PLAN OF DISTRIBUTION......................... 13
DESCRIPTION OF SECURITIES.................... 13
LEGAL MATTERS................................ 19
EXPERTS...................................... 19
AVAILABLE INFORMATION........................ 19